Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

✍ Scribed by Alan Garber; Robert Henry; Robert Ratner; Pedro A Garcia-Hernandez; Hiromi Rodriguez-Pattzi; Israel Olvera-Alvarez; Paula M Hale; Milan Zdravkovic; Bruce Bode

• Book ID: 117303462
• Publisher: The Lancet
• Year: 2009
• Tongue: English
• Weight: 267 KB
• Volume: 373
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/s0140-6736(08)61246-5